Peginterferon Lambda-1a
Sponsors
Bristol-Myers Squibb, EIT Pharma, Inc., Stanford University, University Health Network, Toronto, Icahn School of Medicine at Mount Sinai
Conditions
COVID-19Covid-19Covid19Hepatitis CHepatitis C VirusHepatitis C Virus (HCV)Hepatitis D, ChronicHepatitis Delta Virus
Phase 2
A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection
CompletedNCT02765802
Start: 2016-10-19End: 2018-12-12Updated: 2026-09-08
Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19
CompletedNCT04331899
Start: 2020-04-25End: 2021-05-06Updated: 2021-11-30
Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19
CompletedNCT04354259
Start: 2020-05-13End: 2022-12-08Updated: 2023-12-13
Interferon Lambda Therapy for COVID-19
WithdrawnNCT04388709
Start: 2020-09-30End: 2021-02-05Updated: 2021-02-26
Phase 3
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
CompletedNCT01598090
Start: 2012-06-14End: 2015-05-15Updated: 2019-07-31
Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
CompletedNCT01718158
Start: 2013-01-31End: 2014-10-31Updated: 2015-10-09
Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C
CompletedNCT01754974
Start: 2013-03-31End: 2014-09-30Updated: 2015-01-28
TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19
NCT04967430
Start: 2021-08-27End: 2022-06-30Target: 763Updated: 2022-04-05
Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV
NCT05070364
Start: 2021-12-21End: 2025-01-15Target: 150Updated: 2023-08-25